Literature DB >> 8344486

Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53.

J W Ludlow1.   

Abstract

The oncogenic property of simian virus 40 depends in large part on the function of the virus-coded T-antigen. Although the precise mechanism of how T functions during neoplastic transformation is not clear, some answers to this question may lie in our understanding the nature of the proteins found to complex with T. The cellular protein p53 is perhaps the most extensively studied protein in this regard. Recently, p53 was defined as a growth suppressor protein. At about this same time, T was found to complex with another cell growth suppressor protein, the product of the retinoblastoma susceptibility gene. It has since become apparent that complex formation between these proteins affects their individual growth-modulating activities. Quite often this alteration of activity correlates with an uncontrolled proliferative state of the cell. Thus, transformation by SV40 is thought to involve complex formation between the viral T oncoprotein and cellular growth suppressor proteins. This complex formation is believed to result in nullification of the growth suppressor protein properties, thus increasing the propensity of the cell toward uncontrolled growth, the hallmark of neoplastic transformation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8344486     DOI: 10.1096/fasebj.7.10.8344486

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  39 in total

Review 1.  DNA replication and cell cycle in plants: learning from geminiviruses.

Authors:  C Gutierrez
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

2.  The MRE11-NBS1-RAD50 pathway is perturbed in SV40 large T antigen-immortalized AT-1, AT-2 and HL-1 cardiomyocytes.

Authors:  N A Lanson; D B Egeland; B A Royals; W C Claycomb
Journal:  Nucleic Acids Res       Date:  2000-08-01       Impact factor: 16.971

3.  Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells.

Authors:  K C Thome; A Radfar; N Rosenberg
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Neoplastic transformation and angiogenesis in the thymus of transgenic mice expressing SV40 T and t antigen under an L-pyruvate kinase promoter (SV12 mice).

Authors:  Bernadette Nabarra; Christiane Pontoux; Cecile Godard; Mary Osborne-Pellegrin; Sophie Ezine
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

5.  Immortalized glomerular endothelial cells transfected.

Authors:  K Nitta
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-01       Impact factor: 2.416

Review 6.  Angiogenesis in transgenic models of multistep carcinogenesis.

Authors:  M G D' Angelo; T Afanasieva; A Aguzzi
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

7.  Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control.

Authors:  S R Bartz; M E Rogel; M Emerman
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Macrophage cell lines use CD81 in cell growth regulation.

Authors:  Whitney J Mordica; Keith M Woods; Rollie J Clem; A Lorena Passarelli; Stephen K Chapes
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-01-30       Impact factor: 2.416

9.  Genetic and epigenetic characteristics of gastric cancers with JC virus T-antigen.

Authors:  Satoshi Yamaoka; Hiroyuki Yamamoto; Katsuhiko Nosho; Hiroaki Taniguchi; Yasushi Adachi; Shigeru Sasaki; Yoshiaki Arimura; Kohzoh Imai; Yasuhisa Shinomura
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

10.  Activation of PyMT in beta cells induces irreversible hyperplasia, but oncogene-dependent acinar cell carcinomas when activated in pancreatic progenitors.

Authors:  Yi-Chieh Nancy Du; David S Klimstra; Harold Varmus
Journal:  PLoS One       Date:  2009-09-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.